Omeprazol Aurovitas Pharma (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Aurovitas Pharma, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Aurovitas Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Aurovitas Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success when used with antibiotics. - NSA‑ID‑induced gastropathy: reduces risk of ulcer formation in patients requiring chronic NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain or discomfort. - Flatulence: mild bloating. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Clostridioides difficile‑associated colitis. - Acute interstitial nephritis. - Low magnesium levels (hypomagnesemia) with long‑term use. - Bone fractures (hip, wrist, spine) associated with prolonged therapy. - Liver enzyme elevations (hepatitis).

When prescribing Omeprazol Aurovitas Pharma, clinicians should consider several safety aspects: - Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for magnesium deficiency and bone health. - Use the lowest effective dose: limit duration to the shortest period required. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Store at ambient temperature: keep in the original pack, protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atorvastatin: increased plasma concentrations, higher risk of myopathy. - Warfarin: potential increase in INR, requiring closer monitoring.

Moderate Interactions (Monitor Closely): - Digoxin: elevated levels may occur, monitor serum concentrations. - Methotrexate: reduced renal clearance, watch for toxicity. - Ketoconazole and itraconazole: decreased absorption, may need dose adjustment. - Phenytoin: altered metabolism, monitor therapeutic levels.